Asciminib Hydrochloride Patent Expiration
Asciminib Hydrochloride is Used for treating Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML). It was first introduced by Novartis Pharmaceuticals Corp
Asciminib Hydrochloride Patents
Given below is the list of patents protecting Asciminib Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Scemblix | US12252479 | Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide | May 17, 2040 | Novartis |
| Scemblix | US11407735 | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide | May 14, 2040 | Novartis |
| Scemblix | US12252478 | Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide | May 14, 2040 | Novartis |
| Scemblix | US8829195 | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | May 13, 2033 | Novartis |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Asciminib Hydrochloride's patents.
Latest Legal Activities on Asciminib Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Asciminib Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 27 Dec, 2023 | US8829195 |
| transaction for FDA Determination of Regulatory Review Period | 30 Nov, 2023 | US8829195 |
| Second letter to regulating agency to determine regulatory review period | 26 Jan, 2023 | US8829195 |
| Letter from FDA or Dept of Agriculture re PTE application | 10 Jan, 2023 | US8829195 |
| Post Issue Communication - Certificate of Correction | 23 Aug, 2022 | US11407735 |
| Recordation of Patent Grant Mailed Critical | 09 Aug, 2022 | US11407735 |
| Patent Issue Date Used in PTA Calculation Critical | 09 Aug, 2022 | US11407735 |
| Email Notification Critical | 21 Jul, 2022 | US11407735 |
| Issue Notification Mailed Critical | 20 Jul, 2022 | US11407735 |
| Application Is Considered Ready for Issue Critical | 07 Jul, 2022 | US11407735 |
Asciminib Hydrochloride's Family Patents
